Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo

First Page		Document Content
Date: 2015-03-04 03:17:09 Janus kinase inhibitor Hsp90 inhibitors Janus kinase 2 Hsp90 Myelofibrosis Heat shock protein Essential thrombocytosis Medicine Biology Ruxolitinib		Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo Add to Reading List Source URL: medicalxpress.com Download Document from Source Website File Size: 17,62 KB Share Document on Facebook

	Microsoft Word - Daumantas_Matulis_LT DocID: 1qBj0 - View Document
	Akt and CHIP coregulate tau degradation through coordinated interactions Chad A. Dickey†, John Koren, Yong-Jie Zhang‡, Ya-fei Xu‡, Umesh K. Jinwal*, Morris J. Birnbaum§, Bobby Monks§, Mei Sun¶, Jin Q. Cheng¶, DocID: 1967E - View Document
	Life !Sciencs, VoL 61, No. 4, pp,1!J59 chpyTightE?bevierscience Inc. Printed in the USA. All rights reurd 0024-32mp7t .oo PII SOO24 DocID: 13E33 - View Document
	Vol. 268, No. 3, Issue of January 25, pp,1993 Printed in U.S.A. THEJOURNALOF BIOLOGICAL CHEMISTRYby The American Society for Biochemistry and Molecular Biology, Inc DocID: 13BFf - View Document
	Pharmacol. Ther. Vol. 79, No. 2, pp. 129–168, 1998 Copyright © 1998 Elsevier Science Inc. ISSN $19.00 PII S0163 DocID: 13B8G - View Document